Search Results - "Gomez, M. Domine"

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study by Thomas, M., Ponce Aix, S., Navarro Mendivil, A., Riera Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Mauri, C., Domine Gomez, M., Kollmeier, J., Sadjadian, P., Fröhling, K.-P., Huber, R.M., Wolf, M.

Get full text

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) by Angelats, L., Garcia Campelo, M.R., Bernabe Caro, R., Arriola Aperribay, E., Calvo de Juan, V., Barba Joaquín, A., Vinolas Segarra, N., Gil Moreno, M.D.L.L., Vilà Martinez, L., Juan Vidal, O.J., Vilariño Quintela, N., Cobo, M., Sais, E., Domine Gomez, M., Fernandez Nuñez, N., Coves Sarto, J., Marse Fabregat, R., Esteve Gomez, A.M., Rodríguez-Abreu, D., Carcereny Costa, E.

Get full text

Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Dragnev, K.H., Owonikoko, T.K., Csoszi, T., Maglakelidze, M., Beck, J.T., Domine Gomez, M., Lowczak, A., Fulop, A., Hoyer, R.J., Hanna, W., Lowry, P., Aljumaily, R., Chiu, V.K., Bulat, I., Yang, Z., Roberts, P.J., Antal, J.M., Malik, R.K., Morris, S.R., Weiss, J.M.

Get full text

First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG) by Carcereny Costa, E., Rodriguez-Abreu, D., Guirado, M., López-Castro, R., Massutí, B., Bosch Barrera, J., Nogueron Martnez, E., Sala Gonzalez, M.A., Domine Gomez, M., Del Barco Morillo, E., Cerezo Gonzalez, S., Dorta Suarez, M., Casal Rubio, J., Camps, C., Muñoz, M.A., de las Peñas, R., Ortega dominguez, J.A., Gonzalez-Larriba, J.L., Bernabe Caro, R., Provencio Pulla, M.

Get full text

Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy by Farina, B., Ramos Guerra, A. D., Miras, C. Palacios, Madueno, G. Gallardo, Munoz-Barrutia, Arrate, Peces-Barba, G. R., Maceiras, L. Seijo, Corral, J., Gil-Bazo, I., Gomez, M. Domine, Ledesma-Carbayo, M. J.

“…with an approximate 5-years survival rate of 13% from diagnosis. The potential of computational image analysis to provide decision support in oncology and the…”
Get full text

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study by Thomas, M., Ponce-Aix, S., Navarro, A., Riera-Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Dómine Gómez, M., Kollmeier, J., Sadjadian, P., Fröhling, K -P, Huber, R.M., Wolf, M., Pall, Georg, Surmont, Veerle, Bosquee, Léon, Germonpré, Paul, Brückl, Wolfgang, Grah, Christina, Herzmann, Christian, Leistner, Rumo, Meyer, Andreas, Müller, Lothar, Schmalz, Oliver, Scholz, Christian, Schröder, Michael, Serke, Monika, Wesseler, Claas, Brandts, Christian, Kopp, Hans-Georg, Blau, Wolfgang, Griesinger, Frank, Campelo, Maria Rosario Garcia, Garcia, Yolanda Garcia, Perez, José Manuel Trigo

“…The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve…”
Get full text

102P Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS by Rubio Perez, J., Fernández Ochoa, M., Villalba Cuesta, P.L., Avedillo Ruidiaz, M., Rojo, F., Domine Gomez, M.

Get full text

Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database by de Castro Carpeño, J., Dols, M. Cobo, Gomez, M. Domine, Gracia, P. Ruiz, Crama, L., Campelo, M.R. Garcia

Get full text

1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) by Felip, E., Krebs, M.G., Carcereny, E., Smeland, K.B., Arriola, E., Llacer Perez, C., Thompson, J., Paz-Ares, L., Domine Gomez, M., Olivares, J.R., Vinolas Segarra, N., García-Campelo, M.R., Ortega Granados, A.L.O., Chisamore, M., Micklem, D., McCracken, N., Rayford, A., Oliva, C., Gorcea-Carson, C., Spicer, J.

Get full text

939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial by Casarrubios, M., Cruz-Bermudez, A., Sierra-Rodero, B., Martinez, C., Nadal, E., Insa Molla, M.A., Martinez, J. Mosquera, Ojea, C. Gonzalez, Gomez, M. Domine, Tarruella, M. Majem, Abreu, D. Rodriguez, Martinez-Marti, A., De Castro Carpeno, J., Dols, M. Cobo, Vivanco, G. Lopez, Caro, R. Bernabe, Segarra, N. Vinolas, Aranda, I.C. Barneto, Sureda, B. Massuti, Pulla, M. Provencio

Get full text

1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain by Garcia Campelo, M.R., Domine Gomez, M., De Castro Carpeno, J., Moreno Vega, A.L., Ponce Aix, S., Arriola, E., Carcereny Costa, E., Majem Tarruella, M., Huidobro Vence, G., Esteban Gonzalez, E., Fuentes Pradera, J., Ortega Granados, A.L.O., Guillot Morales, M., Massuti Sureda, B., Vila Martinez, L., Blasco Cordellat, A., Fajardo, C.A., Crama, L., Lerones Laborda, N., Cobo Dols, M.

Get full text

973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC by Garassino, M.C., Gadgeel, S.M., Speranza, G., Felip, E., Esteban Gonzalez, E., Domine Gomez, M., Hochmair, M.J., Powell, S.F., Bischoff, H., Peled, N., Grossi, F., Jennens, R., Reck, M., Hui, R., Garon, E.B., Kurata, T., Gray, J.E., Schwarzenberger, P.O., Jensen, E., Rodriguez Abreu, D.

Get full text

157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy by Casarrubios, M., Cruz-Bermudez, A., Sierra-Rodero, B., Nadal, E., Insa Molla, M.A., Garcia Campelo, M.R., Garcia Benito, C., Domine Gomez, M., Majem Tarruella, M., Rodriguez-Abreu, D., Martinez, A., De Castro Carpeno, J., Cobo Dols, M., Lopez Vivanco, G., Vinolas Segarra, N., Barneto Aranda, I.C., Viteri, S., Massuti Sureda, B., Provencio Pulla, M.

Get full text

160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I by Ponce Aix, S., Carcereny Costa, E., Bosch-Barrera, J., Felip Font, E., Guirado, M., Coves Sarto, J., Majem Tarruella, M., Juan Vidal, O.J., Dalmau Portulas, E., Diz, P., Ortega Granados, A.L.O., Domine Gomez, M., Blasco Cordellat, A., Mosquera Martinez, J., Sala Gonzalez, M.A., Dorta, M., Calvo de Juan, V., Zugazagoitia, J., Enguita, A.B., Paz-Ares, L.

Get full text

1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study) by Calvo, V., Carcereny Costa, E., Guirado, M., Ortega Granados, A.L., Lopez Castro, R., Rodriguez-Abreu, D., Garcia Campelo, R., del Barco Morillo, E., Juan-Vidal, O., Camps, C.J., Gonzalez-Larriba, J.L., Domine Gomez, M., Trigo Perez, J.M., Cobo Dols, M., Cerezo Gonzalez, S., Calzas Rodriguez, J., Massuti Sureda, B., Bosch-Barrera, J., Moran, T., Provencio Pulla, M.

Get full text

1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting by Blanco, R., Nadal, E., Loutfi, S., Gomez, M. Domine, Saldaña, J., Gamero, J. Alfaro, Gonzalez-Larriba, J.L., Balea, B. Campos, Sarrio, R. Girones, Hidalgo, J., Barba, A., Tarruella, M. Majem, Marquez, D., Ureste, M. Martin, Hernández, A. Olaverri, Balsalobre, J., Vidal, O.J. Juan

Get full text

1672PMaintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study by Thomas, M, Ponce Aix, S, Navarro Mendivil, A, Riera Knorrenschild, J, Schmidt, M, Wiegert, E, Kapp, K, Mauri, C, Domine Gomez, M, Kollmeier, J, Sadjadian, P, Fröhling, K-P, Huber, R M, Wolf, M

Get full text

1241PImmune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients by Laza-Briviesca, R, Cruz-Bermudez, A, Casarrubios, M, Nadal, E, Molla, M A Insa, García-Campelo, M-R, Huidobro, G, Gomez, M Domine, Tarruella, M Majem, Abreu, D Rodriguez, Martinez-Marti, A, Carpeno, J De Castro, Dols, M Cobo, Vivanco, G López, del Barco Morillo, E, Bernabé, R, Viñolas, N, Aranda, I C Barneto, Sureda, B Massuti, Provencio, M

“…Abstract Background Immunotherapy has become the main therapy in advanced NSCLC patients, but recently, combination with chemotherapy in locally advanced…”
Get full text

1576PEfficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC by Trigo Perez, J M, Felip, E, Brunsvig, P, Helland, A, Viñolas, N, Ponce Aix, S, Carcereny Costa, E, Domine Gomez, M, Arriola, E, Garcia Campelo, R, Spicer, J, Thompson, J R, Ortega Granados, A L, Holt, R J, Lorens, J B, Shoaib, M, Siddiqui, A, Schmidt, E V, Chisamore, M J, Krebs, M G

“…Abstract Background The RTK AXL is implicated in epithelial-to-mesenchymal transition, negative regulation of anti-tumor immunity and resistance to multiple…”
Get full text